GMR Solutions stock
GMRSNYSEGMR Solutions Inc., HealthcareISIN US38013D1063
56Score 56 out of 100, Neutral
Price and trend
87 / 100
Price history
−19% since 2026The chart shows daily closing prices since 13 May 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 28% below its 52-week high. Largest decline since 13 May 2026: 40% (July 2026 to October 2026).
Chart figures for advanced users
- SMA 50$11.27
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.30
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.42
- The lowest closing price of the last twelve months.
- Resistance$15.74
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GMR Solutions Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $610.45M, is number 48 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.74B (down 4% year on year) and earnings of $206.23M (up 910.5%).
- For fiscal 2026, analysts expect on average revenue of $6.03B (up 5.1%) and adjusted earnings per share of $1.73.
Show more
- MEQIRI Score 56 out of 100 (Neutral): rank 322 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 169% of earnings over the last 12 months.Fundamentals 65
Weaknesses
- High debtDebt 5.07 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 28
- Interest barely coveredOperating profit covers interest only 1.7 times.Stability 28
- Volatile share priceVolatility 65% a year over the last 12 months.Stability 28
Its standout strength is technical analysis, while momentum and stability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 57 to 56.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 4.5). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 4% on the prior year. Revenue has grown solidly since 2023, at about 3% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 39%, operating 14%, net 4%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 8 Feb 2027in 87 days
- Last reported
- 9 Nov 2026EPS reported $0.64 (expected $0.50)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.730.0%
- Revenue
- $6.03B0.0%
- Earnings per share
- $1.780.0%
- Revenue
- $6.37B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +3.5%Full-year guidance reiterated: revenue of $5.89 billion to $6.18 billion and adjusted EBITDA of $1.135 billion to $1.195 billion.
“We continue to expect revenue in the range of $5.89 billion to $6.18 billion, our adjusted EBITDA in the range of $1.135 billion to $1.195 billion and total cash used for CapEx and aircraft financing between 5.1% and 5.3% of total revenue.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $15,000 in total. 6 insiders sold, $28.71M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Van Horne EdwardSale
14 Sept 2026, President & COO
- Shares
- 262,278
- Price
- $12.20
- Value
- $3.2M
- Tierney Brian ScottSale
14 Sept 2026, EVP & CFO
- Shares
- 265,794
- Price
- $12.20
- Value
- $3.24M
- Loporcaro NicolaSale
14 Sept 2026, Chairman & CEO
- Shares
- 1,457,102
- Price
- $12.20
- Value
- $17.78M
Show 4 more
- Jacoba LisaSale
14 Sept 2026, EVP & CHRO
- Shares
- 92,680
- Price
- $12.20
- Value
- $1.13M
- Hall JessicaSale
14 Sept 2026, Chief Accounting Officer
- Shares
- 23,687
- Price
- $12.20
- Value
- $288,981
- Cook Thomas A ASale
14 Sept 2026, EVP, GC & Secretary
- Shares
- 251,882
- Price
- $12.20
- Value
- $3.07M
- Jacoba LisaPurchase
14 May 2026, EVP & CHRO
- Shares
- 1,000
- Price
- $15.00
- Value
- $15,000
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at GMR Solutions
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 56
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- RHÖN-KLINIKUMRHK.DE $1.08B58
- Ramsay Générale de SantéGDS.PA $1.05B39
- Clínica BavieraCBAV.MC $938.01M80
- TerveystaloTTALO.HE $864.19M51
- Strata Critical MedicalSRTA $515.38M46
- M1 KlinikenM12.DE $406.28M74
- Starling OncologySTLN $382.47M26
- Viemed HealthcareVMD $345.21M65
ETFs that hold GMR Solutions
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.